Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Aug 27, 2020
|
staff reporter

NEW YORK – Share prices for several diagnostic companies declined sharply on Thursday after Abbott Laboratories and the US Food and Drug Administration announced that the firm had received Emergency Use Authorization for a rapid, low-cost SARS-CoV-2 antigen test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

What's Popular?

In Business News

  1. 10x Genomics, Bio-Rad Laboratories Subsidiary Celsee Headed to Trial in Single-Cell IP Suit

  2. People in the News: New Appointments at Mission Bio, Akoya Biosciences, Micronoma, More

  3. In Brief This Week: Bio-Techne, Dante Labs, Metagenomi, Applied DNA Sciences, Caris Life Sciences

  4. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

  5. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.